Table 2.
Outcomes in patients who received triple therapy versus no triple therapy.
| Variables | Triple Therapy (n = 47) |
Standard Care (n = 47) |
p |
|---|---|---|---|
| Hospital mortality, No. (%) | 19 (40.4) | 19 (40.4) | 1.000 |
| ICU mortality, No (%) | 17 (36.2) | 18 (38.3) | 0.831 |
| RRT for AKI, No. (%) | 11 of 38 (28.9) | 11 of 32 (34.4) | 0.626 |
| ICU LOS, median (IQR), days | 11.0 (7.0–19.0) | 10.0 (5.0–17.0) | 0.491 |
| Hospital LOS, median (IQR), days | 19.0 (9.0–26.0) | 14.0 (8.0–23.0) | 0.346 |
| Duration of vasopressors, median (IQR), h | 84.2 (37.0–169.3) | 62.5 (32.6–105.9) | 0.324 |
| ΔSOFA score in 72 h, mean ± SD | 1.3 ± 4.1 | 0.1 ± 4.7 | 0.390 |
| ΔPCT in 72 h, median (IQR), ng/mL | 0.1 (−55.0–9.1) | 2.5 (−3.2–4.4) | 0.268 |
ICU: intensive care unit; AKI: acute kidney injury; RRT: renal replacement therapy; LOS: length of stay; IQR: interquartile range; SOFA: Sepsis-Related Organ Failure Assessment; PCT: procalcitonin.